F1000Research,
Journal Year:
2022,
Volume and Issue:
11, P. 1176 - 1176
Published: Oct. 17, 2022
Background:
Parkinson's
disease
is
an
attractive
model
to
extend
research
towards
a
better
understanding
of
the
interrelationship
between
genes
and
environment
(exposome)
therefore
ideal
for
polypharmacological
approach
due
its
clinical
heterogeneity.Methods:
In
this
paper,
we
present
series
chemical
scaffolds
extracted
from
ChEMBL
30
Database,
with
two
or
more
targets
PD-related
proteins
obtained
through
chemoinformatics
methods.
This
way,
describe
first
adaptation
Dual
Activity
Difference
(DAD)
map
that
allows
direct
identification
"dual
activity
cliffs".Results:
We
identified
25
antiparkinson
small
molecules
whose
pharmacological
are
directed
dopaminergic
muscarinic
acetyl
choline
M1-M5
receptors;
2
three
norepinephrine
transporter,
D1-D2
6
both
transporter
receptors
1
adenosine
A2a
Dopamine
D1-D5
receptors.Conclusion:
Chemoinformatics
methods
36
related
disease.
Demonstrating
design
drugs
opportunity
in
PD.
Chemical Society Reviews,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 1, 2025
Hydrogels
are
emerging
as
promising
candidates
for
brain–computer
interfaces.
This
review
highlights
the
current
advancements
in
implantable
hydrogel
electrodes
neural
signal
recording,
neuromodulation,
and
brain
disorder
treatment.
Current Issues in Molecular Biology,
Journal Year:
2025,
Volume and Issue:
47(3), P. 174 - 174
Published: March 6, 2025
Parkinson's
disease
(PD)
is
the
second
most
common
neurodegenerative
disease,
and
its
prevalence
expected
to
double
in
next
30
years.
Currently,
no
effective
treatment
exists
for
disease.
Thus,
research
has
focused
on
discovering
new
natural
compounds
with
strong
neuroprotective
potential.
This
study
aimed
investigate
effects
of
methanol
extract
Desmodesmus
arthrodesmiformis
EM13
(DaMe)
mitochondrial
damage
pathway
an
vitro
model
PD.
The
isolate
was
first
grown
under
appropriate
culture
conditions,
then
prepared
use
experiments.
total
lipid
protein
contents,
fatty
acid
composition,
elemental
content
DaMe
were
subsequently
determined.
Human
SH-SY5Y
neuroblastoma
cells
pretreated
nontoxic
concentrations
before
6-hydroxydopamine
(6-OHDA)
toxicity.
Pretreatment
at
100,
250,
500
µg/mL
showed
a
effect
6-OHDA-induced
by
decreasing
reactive
oxygen
species
(ROS)
production,
oxidant
status
(TOS),
increasing
antioxidant
capacity
(TAC),
membrane
potential
(ΔΨm),
oxidative
DNA
damage,
regulating
gene
expressions
related
PD
apoptosis.
Given
results
our
study,
we
suggest
that
can
be
used
as
source
producing
drugs
dietary
supplements
intended
treat
Bulletin of the Korean Chemical Society,
Journal Year:
2025,
Volume and Issue:
unknown
Published: March 17, 2025
Abstract
Parkinson's
disease
(PD)
is
a
progressive
neurodegenerative
caused
by
loss
of
dopaminergic
neurons
in
the
substantia
nigra.
Monoamine
oxidase‐B
(MAO‐B)
inhibition
promising
strategy
for
modification.
Here,
we
synthesized
series
2,6‐diarylbenzo[
d
]oxazoles
and
identified
two
potent
selective
hMAO‐B
inhibitors:
4,4′‐(benzo[
]oxazole‐2,6‐diyl)diphenol
4a
(IC
50
=
0.182
μM)
4‐(2‐(3‐fluorophenyl)benzo[
]oxazol‐6‐yl)phenol
4f
0.184
μM).
Molecular
modeling
indicated
that
benzoxazole
core
interacts
hydrophobically
within
active
site,
contributing
to
their
inhibitory
potency.
Both
compounds
demonstrated
reversible
or
partially
neuroprotective
effects
MPP
+
‐induced
neurotoxicity
assay
using
human
neuroblastoma
cells.
Additionally,
both
exhibited
good
microsomal
stability
lacked
significant
perturbation
hERG
channel
activity.
While
showed
CYP
against
some
isozymes,
had
minimal
on
isozyme
activities,
suggesting
more
favorable
pharmacokinetic
profile.
Based
these
findings,
presents
therapeutic
candidate
treatment
PD.
Journal of Biomolecular Structure and Dynamics,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 16
Published: April 29, 2024
In
lysozyme
amyloidosis,
fibrillar
aggregates
of
are
associated
with
severe
renal,
hepatic,
and
gastrointestinal
manifestations,
no
definite
therapy.
Current
drugs
now
being
tested
in
amyloidosis
clinical
trials
as
aggregation
inhibitors
to
mitigate
disease
progression.
The
tetracycline
group
among
antimicrobials
use
is
phase
II
trials,
whereas
some
macrolides
cephalosporins
have
shown
neuroprotection.
the
present
study,
two
cephalosporins,
ceftazidime
(CZD)
cefotaxime
(CXM),
a
glycopeptide,
vancomycin
(VNC),
evaluated
for
inhibition
amyloid
hen
egg
white
(HEWL)
under
conditions
(i)
4
M
guanidine
hydrochloride
(GuHCl)
at
pH
6.5
37°
C,
(ii)
At
1.5
65
°C.
Fluorescence
quench
titration
molecular
docking
methods
report
that
CZD,
CXM,
VNC
interact
more
strongly
partially
folded
intermediates
(PFI)
comparison
protein's
natural
state
(N).
However,
only
CZD
CXM
proficiently
inhibit
aggregation.
Transmission
electron
microscopy,
tinctorial
assessments,
kinetics
all
support
oligomer-level
inhibition.
Transition
structures
CZD-HEWL
CXM-HEWL
by
circular
dichroism
(CD).
On
other
hand,
kinetic
variables
soluble
fraction
assays
point
localized
association
monomers.
Intrinsic
fluorescence
(IF),1-Anilino
8-naphthalene
sulphonic
acid,
CD
demonstrate
structural
conformational
modifications
redesigning
PFI.
GuHCl-induced
unfolding
differential
scanning
fluorimetry
suggested
PFI
monomers
bound
exhibited
partial
stability.
Our
results
mechanisms
function
both
solution
conditions,
creating
novel
avenue
screening
putative
drug
repurposing.
We
extend
our
proposed
designing
physical
considering
shorter
time
frames
foolproof
methods.Communicated
Ramaswamy
H.
Sarma.
Internal Medicine,
Journal Year:
2022,
Volume and Issue:
61(24), P. 3719 - 3722
Published: May 13, 2022
Vitamin
B6
(VB6)
is
essential
to
heme
synthesis,
and
its
deficiency
can
lead
anemia.
VB6
anemia
typically
microcytic,
hypochromic,
sideroblastic.
a
well-recognized
complication
of
levodopa/carbidopa
therapy,
as
metabolism
levodopa
dopamine
VB6-dependent,
carbidopa
irreversibly
forms
bonds
deactivates
VB6.
We
herein
report
75-year-old
man
with
advanced
Parkinson's
disease
who
developed
severe
due
intestinal
gel
therapy.
His
was
promptly
resolved
simple
oral
supplementation
pyridoxal
phosphate
hydrate.
mimic
myelodysplastic
syndrome
thus
an
important
differential
diagnosis
for
patients
administered
levodopa/carbidopa.
Metabolites,
Journal Year:
2024,
Volume and Issue:
14(2), P. 106 - 106
Published: Feb. 5, 2024
Parkinson’s
disease
(PD),
a
widely
recognized
neurodegenerative
disorder,
is
characterized
by
spectrum
of
symptoms
including
motor
fluctuations
and
dyskinesia.
Neuroinflammation
dysregulation
adipokines
are
increasingly
implicated
in
the
progression
PD.
This
preliminary
study
investigated
levels
inflammatory
biomarkers
adipokines,
namely
interleukin-6
(IL-6),
tumor
necrosis
factor
α
(TNF-α),
C-reactive
protein
(CRP),
visfatin,
progranulin,
25(OH)-vitamin
D
52
PD
patients,
divided
equally
between
those
with
without
dyskinesia
26
healthy
controls.
Significant
differences
IL-6,
TNF-α,
progranulin
were
noted
groups.
Patients
exhibited
notably
higher
IL-6
compared
to
controls,
TNF-α
was
significantly
elevated
both
patient
groups
relative
control
group.
Additionally,
visfatin
patients
as
opposed
dyskinesia,
non-dyskinetic
group
The
findings
highlight
potential
role
examined
pathophysiology
Changes
tested
might
be
associated
its
such
